CCM/Market Reports-/Market of Paclitaxel Injection in China

¡¡

(home)
CCM
consultancy
Market reports
Trade Analysis
newsletters & Information
conferences & events
coming report
ValoTracer
about us
careers 
contact
Always Primary Findings
Online Payment
samples
 

click here for sample pages

 

CCM>Market Reports>

 

No. 0007P006 Market of Paclitaxel Injection in China  - Edition(1)

 

 

About This Report:

 

Report edition:  2010 edition(1)
Language version: English
Document type: PDF File,(*.pdf)
For ready report --    
  Finished in: Aug 2010 ,edition(1)
  Total pages: 51
  Delivery: Delivery within 1-1 work days by email
  Price/copy: - USD6500.00 for single user
    -USD16250.00 for corporate license/site license
For update report --  
  Delivery time: Delivery within 25-35 work days by email
  Price/copy: - USD8000.00 for single user PDF
    - USD20000.00 for corporate license/site license

 

* The corporate license/site license is only for the sole and confidential use within the subscriber company and its affiliates in which the subscriber company owns, directly or indirectly, a fifty percent or greater, financial interest.

 

Report Edition List:

 

Version Finished in Availability Language   Pages   Delivery Price/Copy (For single user)
update report - update on request English - within 25-35 work days by email USD8000.00

 

 

Description:

 

Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.

Chinese paclitaxel injection industry has witnessed significant development from 2005～2009. On one hand, since 2005, Chinese government has issued a series of policies related to China’s pharmaceutical industry like healthcare reform. How do they influence the paclitaxel injection industry? On the other hand, paclitaxel injection has enjoyed the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?

For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role. Owing to the increasing cultivated planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How did the paclitaxel APIs and paclitaxel injection manufacturers respond to this change? In 2009, Sichuan Jiufeng Pharmaceutical Co., Ltd. (Sichuan Jiufeng), the largest producer of paclitaxel injection in China, has increased its output of paclitaxel injection greatly because of the great demand, and then what is the performance of Sichuan Jiufeng in 2010?

What’s more, paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms. How do the pharmaceutical distribution companies distribute the paclitaxel injection, and how does the medicine bidding and purchase platforms for paclitaxel injection are operated?

Besides the aspects mentioned above, what is the production distribution of paclitaxel APIs? What is the development trend of China’s paclitaxel injection? CCM has carried out in-depth research and analysis on each active producer, as well as the whole industry to figure out these questions.

In this report, you can obtain info about:
-  Production distribution of paclitaxel APIs
-  General situation of paclitaxel injection production and its manufacturers
-  Top 2 pharmaceutical distribution companies in China
-  Medicine bidding and purchasing platforms
-  Import and export paclitaxel injection analysis, as well as paclitaxel APIs export analysis
-  Consumption situation of paclitaxel injection
-  Government policy for paclitaxel injection and quality standards of paclitaxel injection
-  circulation model of paclitaxel injection in China

With the information covered in the report, readers can see the general production and consumption situation, circulation model, as well as APIs supply situation for China paclitaxel injection manufacturers in China, which are beneficial for the investors’ decision making.

 

Main Content:

 

No. Content
Page
Executive summary
1
I Development of policy environment for paclitaxel injection in China
3
I-1 Regulation in GMP about paclitaxel injection
4
I-2 Regulation about paclitaxel injection in CP 2000
6
II Production of paclitaxel injection in China
7
II-1 Production data from 2005 to 2009
7
II-2 Regional distribution of paclitaxel injection production
7
II-3 Summary of paclitaxel injection manufacturers in China, 2008&2009
10
II-4 Competition analysis of paclitaxel injection producers
12
III Production of paclitaxel APIs in China
13
IV China’s paclitaxel injection distribution model
17
IV-1 Pharmaceutical distribution business in China
17
IV-1.1 Development history of pharmaceutical distribution business in China
17
IV-1.2 China’s major regional market share of pharmaceutical distribution business
19
IV-1.3 Sales value and concentration of pharmaceutical distribution business in China
20
IV-2 Introduction to distribution of paclitaxel injection with Chinese characteristic
21
V China’s medicine bidding and purchasing platform
23
V-1 Background of medicine bidding and purchasing platform
23
V-2 Flow chart of medicine bidding and purchasing platform
23
V-3 Top two pharmaceutical distribution companies
24
VI Consumption of paclitaxel injection in China
27
VI-1 Overview of anticancer drugs in China
27
VI-1.1 Consumption situation of natural anticancer drugs
28
VI-2 Consumption situation of paclitaxel injection
28
VI-2.1 Consumption in end-user sectors
30
VI-2.1.1 NSCLC
30
VI-2.1.2 Breast cancer
31
VI-2.1.3 Ovarian cancer
32
VI-2.2 Distribution of paclitaxel injection consumption in top five provinces
33
VI-3 Consumption potential analysis of paclitaxel injection in next 5 years
34
VI-3.1 Influencing factors for consumption
34
VI-3.2 Forecast consumption of paclitaxel injection in China, 2010-2015
35
VII Import and export situation in 2009
38
VII-1 Import and export situation for paclitaxel injection
38
VII-2 Export situation for paclitaxel APIs
39
VIII Resource of yew in China
41
IX Profile of major manufacturers of paclitaxel injection in China
44
IX-1 Sichuan Jiufeng Pharmaceutical Co., Ltd.
44
...
IX-10 Youcare Pharmaceutical Group Co., Ltd.
50

LIST OF TABLES
Table I-1 Regulations involving paclitaxel and its related products
Table I-2 Paclitaxel export tax rebate, 2005 to now
Table I-1.1Standard of purified water in China’s GMP
Table I-1.2 Quality standard of purified water
Table I-1.3 Standard of air cleanliness in China’s GMP
Table I-2.1 CP 2000 of paclitaxel injection of China
Table II-3.1 Active paclitaxel injection manufacturers situation in China, 2010
Table II-3.2 Product situation of active paclitaxel injection manufacturers in China, 2010
Table III-3.1 Active paclitaxel APIs manufacturers in China, 2010
Table IV-1.3.1Sales value of pharmaceutical distribution companies in China, 2003-2009
Table VI-1.1 Market share of anticancer drugs in China, 2005-2009
Table VI-1.1.1 Sales value and market share of natural anticancer preparations in China, 2009
Table VI-2.1 Consumption volume of paclitaxel injection in China, 2005-2009
Table VI-2.2 Sales value and growth rate of paclitaxel injection in China, 2005-2009
Table VI-2.1.1.1 Number and growth rate of NSCLC patients in China, 2005-2009
Table VI-2.1.1.2 Consumption volume and growth rate of paclitaxel injection for NSCLC in China, 2005-2009
Table VI-2.1.2.1 Number and growth rate of breast cancer patients in China, 2005-2009
Table VI-2.1.2.2 Consumption volume and growth rate of paclitaxel injection for breast cancer in China, 2005-2009
Table VI-2.1.3.1 Number and growth rate of ovarian cancer patients in China, 2005-2009
Table VI-2.1.3.2 Consumption volume and growth rate of paclitaxel injection for ovarian cancer in China, 2005-2009
Table VI-2.2.1 Sales value and market share of paclitaxel injection in top five provinces in China, 2009
Table VII-1.1 Paclitaxel injection import situation in China, 2009
Table VII-1.2 Paclitaxel injection export situation in China, 2009
Table VII-2.1 Monthly export value of paclitaxel APIs in China, 2009
Table VII-2.2 Major export destinations of paclitaxel APIs from China, 2009
Table VII-2.3 Major exporters of paclitaxel APIs in China, 2009
Table VIII-1 Number of yews in China by province, 2007-2009
Table VIII-2 Number of cultivated yews in China, 2007-2009

LIST OF FIGURES
Figure II-1.1 Production value of paclitaxel injection in China, 2005-2009
Figure II-2.1 Production value distribution of paclitaxel injection in China, 2009, USD
Figure II-2.2 Number of paclitaxel injection manufacturers in different provinces, 2009
Figure II-2.3 Production value structure of paclitaxel injection in China, 2009
Figure III-1.1 Production value of paclitaxel APIs in China, 2005-2009
Figure III-2.1 Production value distribution of paclitaxel APIs in China, 2009, USD
Figure III-2.2 Number of paclitaxel injection manufacturers in different provinces, 2009
Figure III-2.3 Production value structure of paclitaxel APIs in China, 2009
Figure IV-1 Situation of pharmaceutical distribution
Figure IV-1.1.1 Development of pharmaceutical distribution business in China
Figure IV-1.2.1 Geographical distribution of pharmaceutical distribution business by sales value in China, 2009
Figure IV-1.2.2 Market share of pharmaceutical distribution business in China by sales value, 2009
Figure IV-1.3.1 Sales value and market share of top 3 pharmaceutical distribution companies in China, 2003-2009
Figure IV-2.1 Circulation of paclitaxel injection with Chinese characteristic
Figure V-2.1 Flow chart of bidding and purchasing platform
Figure V-3.1 Main business lines of Sinopharm
Figure V-3.1 Main business lines of Shanghai Pharmaceutical
Figure VI-1.1 Sales value and growth rate of anticancer drugs in China, 2005-2009
Figure VI-2.1 Consumption pattern of paclitaxel injection by sales value in China, 2009
Figure VI-2.2 Consumption volume of paclitaxel injection in major segments in China, 2009
Figure VI-3.1.1 CAGR of consumption volume of paclitaxel injection in major end use segments, 2005-2009
Figure VI-3.2.1 Forecast on consumption volume of paclitaxel injection in China, 2010-2014
Figure VI-3.2.2 Forecast on consumption of paclitaxel injection in NSCLC in China, 2010-2014
Figure VI-3.2.3 Forecast on consumption of paclitaxel injection in breast cancer in China, 2010-2014
Figure VI-3.2.4 Forecast on consumption of paclitaxel injection in ovarian cancer in China, 2010-2014
Figure VIII-1 Number of cultivated yews in China, 2007-2009
Figure VIII-2 Geographical distribution of yew’s planting amount in China, 2009

Part of Report: click here for sample pages

Executive Summary

China started clinical application of paclitaxel injection in 1994 with exported products, and then achieved industrialized production when Yunnan Hande Bio-tech Co., Ltd., the first paclitaxel injection producer in China, entered this market. Currently, China is one of the leading consumption areas in the world, capturing over xx% consumption of global market share.

Besides in China, the consumption of paclitaxel injection takes up xx% of total antineoplastic medicines, and the share tends to increase.

And since 2005, China has become one of the largest paclitaxel injection production bases in the world with more and more producers entering the market because of the increasing demand, and its paclitaxel injection production value has increased from USDxx million in 2005 to USDxx million in 2009, with CAGR of xx% for 2005 ~ 2009.

But only some of the paclitaxel injection manufacturers have expanded to foreign market, such as Beijing Double Heron Pharmaceutical Co., Ltd. and Youcare Pharmaceutical Group Co., Ltd., but only in Southeast Asia and Middle East countries like Pakistan (PAK), Philippine, etc. Most of the companies do their business mainly in the domestic market due to the high quality threshold for other countries, especially for developed countries. In 2009, China’s paclitaxel injection export value has reached USDxx through China customs.

As for the import, in 2009, Guangdong Zhongjian Medicine Co., Ltd., Hainan Gaoxiang Medicine Co., Ltd. and Bristol-Myers Squibb (China) are the three main paclitaxel injection importers in China with total import value of USDxx.

Paclitaxel injection in the treatment of the cancer patients is made from paclitaxel APIs which is extracted from yew. China is one of the largest yew production countries in the world with xx million of planting amount in 2009, accounting for xx % of world’s total.

Paclitaxel injection industry does harm to rare plant – Yew, due to little content of paclitaxel in yew and yew’s long growth cycle. Under stricter environmental protection policies, some small-scale APIs manufacturers using natural yews as raw material and investing little in yew planting have been phased out gradually from the market, especially in the latest 3 years. However, it is relatively beneficial for some largest-scale paclitaxel injection manufacturers. With advantages of enough funds to cooperate with some APIs manufactures or develop their own yew planting areas, they are more competitive.

However, China’s yew production amount has witnessed slight increase for three consecutive years from xx million in 2007, thanks to the development of greatly profitable APIs industry. Moreover, export value of paclitaxel APIs still takes up xx%, a large part in China’s total APIs production value.

Because of intense competition in paclitaxel injection industry in China, paclitaxel injection producers have gained lower profit due to the declining paclitaxel injection price and continually high cost of yew in recent years. Paclitaxel injection price has declined in last 2 years in China mainly due to more supply into the market. Price of the paclitaxel injection for domestic manufacturers before 2008 kept at USDxx/dose ～ USDxx/dose, but currently it is USDxx/dose ～ USDxx/dose .

......

(The rest content of this report is omitted.)

Character of CCM' Report:

This multi-client report provides a comprehensive study on the researched subject in China, from aspects of production, technology, import & export, consumption & end uses, etc.

>>
 All the producers in China, either active or idled or potential, have been sourced and contacted. Their situation has been verified and compiled as in the appendix.
>>
 The competitiveness of Chinese production has been discussed in order to uncover the mystery of ever-increasing capability of Chinese manufacturing.
>>
 The import & export analysis for the situation in the recent three years has been conducted.
>>
 The consumption pattern of the researched subject has been carried out in order to breakdown the end uses into different segments. The major end users under each major end use segments have been identified.
>>
 The scientific methodology has been employed to conduct the quantitative forecast on this subject in the future 5-10 years.

The aim of this report is to provide powerful assistance to the strategy group and the management team in making correct decision as how to penetrate the ever-increasing China market and how to catch the maximum commercial opportunities. The report is formulated independently by CCM’s professional market researchers, based on the first-hand and primary data which are analyzed by scientific methodology, confirmed with both manufacturers/end users/traders and legal authorities, and presented in a logic way.

Remark:

If you are not satisfied with the above main content, or if you would like to add additional requirements to the mentioned subject, or if you could not find your interested item(s) via the search engine, you are advised to go to Single-Client Services and Advisor, or Contact Us.